Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
In the treatment of acquired immune deficiency syndrome (AIDS), the diarylpyrimidine (DAPY) analogs etravirine (ETR) and rilpivirine (RPV) have been widely effective against human immunodeficiency virus (HIV) variants that are resistant to other non-nucleoside reverse transcriptase inhibitors (NNRTI...
Saved in:
Main Authors: | Daniel M. Himmel (Author), Eddy Arnold (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020) -
Updated guidelines for the use of rifamycins for the treatment of tuberculosis in HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors
by: Editorial Office
Published: (2004) -
Effect of non-nucleoside reverse transcriptase inhibitors and protease inhibitors on serum levels of myeloperoxidase and C-reactive protein in HIV-infected individuals
by: Danielle Cristyane Kalva Borato, et al.
Published: (2022) -
Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region
by: Tao Zhang, et al.
Published: (2022) -
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
by: Hanh Thi Pham, et al.
Published: (2020)